Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:57:40.084Z.
Calculation as of: 2026-10-06T16:57:40.084Z.
Quote observation: 2026-10-06T16:54:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f827d960650d67e3900ac6098f04a5e2078fd3b8121965df68c70cd2fd602cdf
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$216.34M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$213.71M
EV/EBITDA Ratio
14.31x
TTM Avg
22.76x
3Y Avg
55.61x
5Y Avg
55.61x
Market Cap
$213.50M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$223.45M
EV/EBITDA Ratio
N/A
TTM Avg
1.40x
3Y Avg
1.40x
5Y Avg
1.40x
Market Cap
$208.32M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$208.04M
EV/EBITDA Ratio
N/A
TTM Avg
5.75x
3Y Avg
5.75x
5Y Avg
5.75x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $216.34M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $213.72M | N/A | 16.55x | 16.55x | 16.55x |
| Niagen Bioscience Inc (NAGE)vs › | $213.71M | 14.31x | 22.76x | 55.61x | 55.61x |
| Prelude Therapeutics Incorporated (PRLD)vs › | $213.50M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $221.03M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $211.33M | N/A | 6.24x | 9.83x | 9.83x |
| Keros Therapeutics, Inc. (KROS)vs › | $223.45M | N/A | 1.40x | 1.40x | 1.40x |
| Sionna Therapeutics, Inc. (SION)vs › | $208.32M | N/A | N/A | N/A | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $208.04M | N/A | 5.75x | 5.75x | 5.75x |
| Profound Medical Corp. (PROF)vs › | $225.29M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
